Trial · NCT00838903
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period (156 Weeks) | STARTED | Placebo Plus Metformin | 101 | |
| Treatment Period (156 Weeks) | STARTED | Sitagliptin 100 mg Plus Metformin | 302 | |
| Treatment Period (156 Weeks) | STARTED | Glimepiride 2 mg Plus Metformin | 307 | |
| Treatment Period (156 Weeks) | STARTED | Albiglutide 30 mg Plus Metformin | 302 | |
| Treatment Period (156 Weeks) | Missing Active Treatment Status | Placebo Plus Metformin | 1 | |
| Treatment Period (156 Weeks) | Missing Active Treatment Status | Sitagliptin 100 mg Plus Metformin | 0 | |
| Treatment Period (156 Weeks) | Missing Active Treatment Status | Glimepiride 2 mg Plus Metformin | 0 | |
| Treatment Period (156 Weeks) | Missing Active Treatment Status | Albiglutide 30 mg Plus Metformin | 0 | |
| Treatment Period (156 Weeks) | COMPLETED | Placebo Plus Metformin | 55 | |
| Treatment Period (156 Weeks) | COMPLETED | Sitagliptin 100 mg Plus Metformin | 190 | |
| Treatment Period (156 Weeks) | COMPLETED | Glimepiride 2 mg Plus Metformin | 191 | |
| Treatment Period (156 Weeks) | COMPLETED | Albiglutide 30 mg Plus Metformin | 192 | |
| Treatment Period (156 Weeks) | NOT COMPLETED | Placebo Plus Metformin | 46 | |
| Treatment Period (156 Weeks) | NOT COMPLETED | Sitagliptin 100 mg Plus Metformin | 112 | |
| Treatment Period (156 Weeks) | NOT COMPLETED | Glimepiride 2 mg Plus Metformin | 116 | |
| Treatment Period (156 Weeks) | NOT COMPLETED | Albiglutide 30 mg Plus Metformin | 110 | |
| Follow-up Period (8 Weeks) | STARTED | Placebo Plus Metformin | 101 | |
| Follow-up Period (8 Weeks) | STARTED | Sitagliptin 100 mg Plus Metformin | 302 | |
| Follow-up Period (8 Weeks) | STARTED | Glimepiride 2 mg Plus Metformin | 307 | |
| Follow-up Period (8 Weeks) | STARTED | Albiglutide 30 mg Plus Metformin | 302 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00838903/flow